Large scale genotype‐ and phenotype‐driven machine learning in Von Hippel‐Lindau disease

Von Hippel‐Lindau (VHL) disease is a hereditary cancer syndrome where individuals are predisposed to tumor development in the brain, adrenal gland, kidney, and other organs. It is caused by pathogenic variants in the VHL tumor suppressor gene. Standardized disease information has been difficult to collect due to the rarity and diversity of VHL patients. Over 4100 unique articles published until October 2019 were screened for germline genotype–phenotype data. Patient data were translated into standardized descriptions using Human Genome Variation Society gene variant nomenclature and Human Phenotype Ontology terms and has been manually curated into an open‐access knowledgebase called Clinical Interpretation of Variants in Cancer. In total, 634 unique VHL variants, 2882 patients, and 1991 families from 427 papers were captured. We identified relationship trends between phenotype and genotype data using classic statistical methods and spectral clustering unsupervised learning. Our analyses reveal earlier onset of pheochromocytoma/paraganglioma and retinal angiomas, phenotype co‐occurrences and genotype–phenotype correlations including hotspots. It confirms existing VHL associations and can be used to identify new patterns and associations in VHL disease. Our database serves as an aggregate knowledge translation tool to facilitate sharing information about the pathogenicity of VHL variants.

[1]  Jingcheng Zhou,et al.  The Genotype-Phenotype Association of Von Hipple Lindau Disease Based on Mutation Locations: A Retrospective Study of 577 Cases in a Chinese Population , 2020, Frontiers in Genetics.

[2]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[3]  Shengjie Liu,et al.  Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel–Lindau Disease , 2019, Front. Genet..

[4]  A. Latronico,et al.  New Insights Into Pheochromocytoma Surveillance of Young Patients With VHL Missense Mutations , 2019, Journal of the Endocrine Society.

[5]  Tudor Groza,et al.  Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources , 2018, Nucleic Acids Res..

[6]  Shraddha Pai,et al.  Patient Similarity Networks for Precision Medicine. , 2018, Journal of molecular biology.

[7]  H. Amthauer,et al.  Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. , 2018, Endocrine-related cancer.

[8]  W. Linehan,et al.  In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease , 2018, The Journal of clinical endocrinology and metabolism.

[9]  S. Peng,et al.  Genotype and phenotype correlation in Von Hippel-Lindau disease based on the alteration of HIF-α binding site in VHL protein , 2018 .

[10]  D. Malkin,et al.  Evidence for genetic anticipation in vonHippel-Lindau syndrome , 2018, Journal of Medical Genetics.

[11]  Raymond Dalgleish,et al.  VariantValidator: Accurate validation, mapping, and formatting of sequence variation descriptions , 2017, Human mutation.

[12]  S. Libutti,et al.  Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel–Lindau Disease , 2018, JAMA oncology.

[13]  Lily Hoffman-Andrews The known unknown: the challenges of genetic variants of uncertain significance in clinical practice , 2017, Journal of law and the biosciences.

[14]  Lana X. Garmire,et al.  More Is Better: Recent Progress in Multi-Omics Data Integration Methods , 2017, Front. Genet..

[15]  Steven J. M. Jones,et al.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[16]  J. Kuratsu,et al.  Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan , 2017, Neurologia medico-chirurgica.

[17]  L. Krogh,et al.  Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T) , 2016, Current genomics.

[18]  W. Chung,et al.  Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Budtz-Jørgensen,et al.  Survival and causes of death in patients with von Hippel-Lindau disease , 2016, Journal of Medical Genetics.

[20]  Silvio C. E. Tosatto,et al.  VHLdb: A database of von Hippel-Lindau protein interactors and mutations , 2016, Scientific Reports.

[21]  Seung Jun Lee,et al.  Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma , 2016, BMC Medical Genetics.

[22]  Raymond Dalgleish,et al.  HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.

[23]  Matthew S. Lebo,et al.  Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.

[24]  Heidi L Rehm,et al.  ClinGen--the Clinical Genome Resource. , 2015, The New England journal of medicine.

[25]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[26]  M. Ritchie,et al.  Methods of integrating data to uncover genotype–phenotype interactions , 2015, Nature Reviews Genetics.

[27]  Richard A Armstrong,et al.  When to use the Bonferroni correction , 2014, Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians.

[28]  Benjamin M. Good,et al.  Organizing knowledge to enable personalization of medicine in cancer , 2014, Genome Biology.

[29]  Zhuowen Tu,et al.  Similarity network fusion for aggregating data types on a genomic scale , 2014, Nature Methods.

[30]  E. D. de Vries,et al.  Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations. , 2013, Endocrine-related cancer.

[31]  K. Tamura,et al.  Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey , 2014, Journal of Gastroenterology.

[32]  William R Pearson,et al.  Selecting the Right Similarity‐Scoring Matrix , 2013, Current protocols in bioinformatics.

[33]  M. Kosteljanetz,et al.  Von Hippel-Lindau disease (vHL): National clinical guideline for diagnosis and surveillance in Denmark , 2013 .

[34]  L. Sunde,et al.  National clinical guideline for diagnosis and surveillance in Denmark 3 rd Edition , 2013 .

[35]  S. Richard,et al.  von Hippel–Lindau disease: A clinical and scientific review , 2011, European Journal of Human Genetics.

[36]  S. Uhrig,et al.  Pheochromocytoma in a 2.75‐year‐old‐girl with a germline von Hippel–Lindau mutation Q164R , 2010, American journal of medical genetics. Part A.

[37]  A. V. D. van den Ouweland,et al.  Genetic analysis of von Hippel‐Lindau disease , 2010, Human mutation.

[38]  E. Budtz-Jørgensen,et al.  Surveillance in von Hippel‐Lindau disease (vHL) , 2010, Clinical genetics.

[39]  S. Tavtigian,et al.  In silico analysis of missense substitutions using sequence‐alignment based methods , 2008, Human mutation.

[40]  Peter L Choyke,et al.  Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). , 2007, Surgery.

[41]  Ulrike von Luxburg,et al.  A tutorial on spectral clustering , 2007, Stat. Comput..

[42]  E. Maher,et al.  Genotype–phenotype correlations in von Hippel‐Lindau disease , 2004, Human mutation.

[43]  Kentaro Takahashi,et al.  [Von Hippel-Lindau disease]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[44]  C. Sander,et al.  The amino-acid mutational spectrum of human genetic disease , 2003, Genome Biology.

[45]  Yigong Shi Faculty Opinions recommendation of Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. , 2002 .

[46]  D. Nickerson,et al.  Variation is the spice of life , 2001, Nature Genetics.

[47]  Michael I. Jordan,et al.  On Spectral Clustering: Analysis and an algorithm , 2001, NIPS.

[48]  G. Mortier,et al.  Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene , 2000, Human Genetics.

[49]  C Béroud,et al.  UMD (Universal Mutation Database): A generic software to build and analyze locus‐specific databases , 2000, Human mutation.

[50]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[51]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[52]  S. Richard,et al.  Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.

[53]  F. Chen,et al.  Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. , 1996, Journal of medical genetics.

[54]  P. Schofield,et al.  Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. , 1996, Human molecular genetics.

[55]  B. Zbar,et al.  Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. , 1995, Human molecular genetics.

[56]  P. Choyke,et al.  von Hippel-Lindau disease: genetic, clinical, and imaging features. , 1995, Radiology.

[57]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[58]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[59]  P. Jaccard THE DISTRIBUTION OF THE FLORA IN THE ALPINE ZONE.1 , 1912 .